The American Psychiatric Association plans to update the DSM, the standard reference for psychiatric diagnosis, to incorporate neurobiology for the first time — something the current DSM-5, released in 2013, has been criticized for lacking. A committee member reports the update takes a cautious approach, distinguishing unproven biological 'factors' from measurable 'biomarkers,' of which psychiatry currently has essentially none outside Alzheimer's disease.
Cited advances include a 2025 FDA-approved blood test for Alzheimer's proteins, elevated C-reactive protein levels found in about 30% of depression patients as a possible treatment-response marker, and ongoing genetic risk research. The piece stresses that mental disorders remain loosely defined, overlapping syndromes rather than discrete diseases, making a single clean biomarker for conditions like depression or schizophrenia unlikely anytime soon.
The full dispatch is available from the source below.